RO7119929 + tocilizumab

RO7119929 + tocilizumab is an experimental **combination therapy** comprising two drugs: **RO7119929**, a selective toll-like receptor 7 (TLR7) agonist, and **tocilizumab**, a recombinant humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R). **RO7119929** stimulates the immune response through TLR7 agonism and is being studied as an oral immunomodulatory agent in advanced cancers. **Tocilizumab** blocks IL-6 signaling by binding both soluble and membrane-bound IL-6 receptors, thereby inhibiting downstream pro-inflammatory effects; it is approved for multiple autoimmune and inflammatory diseases, as well as cytokine release syndrome and COVID-19. This combination is under early-stage clinical investigation to evaluate safety, pharmacokinetics, and preliminary clinical activity, particularly in liver cancers and solid tumors with liver metastasis.